Tesamorelin

At a glance

---

What is tesamorelin?

Tesamorelin is a synthetic peptide consisting of all 44 amino acids of human growth hormone-releasing hormone (GHRH), with one key modification: a trans-3-hexenoic acid group attached to the tyrosine at position 1. This modification increases metabolic stability and extends the peptide's half-life compared to native GHRH and the shorter sermorelin fragment (GRF 1-29).^[8]

Developed by Theratechnologies Inc. (initially as TH9507), tesamorelin was approved by the FDA in November 2010 under the brand name Egrifta for a specific indication: reducing excess abdominal fat (visceral adipose tissue) in HIV-infected patients with lipodystrophy.^[1] It was reformulated as Egrifta SV in 2019 (a single-vial preparation), and most recently as Egrifta WR in March 2025, which allows weekly reconstitution instead of daily — reducing patient burden.

Why this matters in the peptide landscape. Tesamorelin is the only GHRH analog that is currently FDA-approved for any indication. Sermorelin was FDA-approved in 1997 but voluntarily withdrawn in 2008. CJC-1295 was never FDA-approved and had its clinical program discontinued. This gives tesamorelin a uniquely strong regulatory position — not just historical approval, but an active, maintained market presence with a current prescribing label.

---

How it works

Tesamorelin works the same way as sermorelin and native GHRH: it binds to the GHRH receptor on pituitary somatotroph cells and triggers the release of endogenous growth hormone. The GH release it stimulates is subject to normal somatostatin feedback — your body's built-in brake — so it is very difficult to produce supraphysiological GH levels with tesamorelin.^[13]

The practical difference from sermorelin is the trans-3-hexenoic acid modification, which makes tesamorelin more resistant to enzymatic degradation. Native GHRH and sermorelin have half-lives of roughly 10-20 minutes; tesamorelin has a modestly longer duration of action, though it is still administered daily by subcutaneous injection.

Detailed mechanism (for advanced readers)

Tesamorelin's mechanism of action is identical to native GHRH at the receptor level:

• Primary target: GHRH receptor (GHRHR) on anterior pituitary somatotroph cells
• Signaling cascade: Gs-coupled activation of adenylyl cyclase, increasing intracellular cAMP, activating PKA. This drives both GH gene transcription and vesicle exocytosis (immediate GH release).
• Feedback regulation: GH release is subject to normal negative feedback via somatostatin (hypothalamic) and IGF-1 (hepatic). This prevents supraphysiological GH levels — the core safety feature of all GHRH-pathway compounds.
• Modification advantage: The trans-3-hexenoic acid group at position 1 protects the N-terminus from dipeptidyl peptidase-IV (DPP-IV) cleavage, extending metabolic stability without altering receptor binding.
• Pulsatility: Tesamorelin preserves the natural pulsatile pattern of GH secretion, unlike exogenous GH injection.^[6]

How it compares to related compounds:

• vs. Sermorelin (GRF 1-29): Both are GHRH-pathway. Sermorelin is 29 amino acids (minimal active fragment); tesamorelin is the full 44 amino acids with an N-terminal modification. Tesamorelin has an active FDA approval; sermorelin's was withdrawn.
• vs. CJC-1295: CJC-1295 uses Drug Affinity Complex (DAC) technology to bind to albumin for a half-life of days. Never FDA-approved. Had a participant death during development.
• vs. Ipamorelin: Works on a completely different receptor (GHS-R1a, the ghrelin receptor). Complementary pathway to tesamorelin/sermorelin.
• vs. Exogenous GH (somatropin): Tesamorelin stimulates endogenous GH production with feedback regulation; exogenous GH bypasses all regulation.

---

What the research says

Tesamorelin has the strongest clinical evidence base of any GHRH analog — including two large Phase 3 RCTs, a meta-analysis, and an active FDA approval. For HIV lipodystrophy, the evidence is robust. For NAFLD, one good trial is promising but limited. For cognition, two consecutive trials have now failed to confirm the one positive result from 2012. For general anti-aging use in non-HIV adults, the data is thin.

Research timeline

Tesamorelin's development was driven by the medical need for treating HIV-associated lipodystrophy:

Human clinical trials

Tesamorelin's human evidence base is centered on its Phase 3 HIV lipodystrophy program, but extends into cognition, NAFLD, and non-HIV body composition:

The quality and scale of tesamorelin's evidence base is notably different from other GH peptides. The Phase 3 program alone enrolled 806 patients across two multicenter international trials — larger than the entire combined clinical dataset for sermorelin, CJC-1295, and ipamorelin in adult populations.

A 2026 meta-analysis pooling five RCTs confirmed the core finding: visceral fat down by -27.71 cm² (95% CI -38.37 to -17.06), trunk fat down, lean body mass up, hepatic fat percentage down, with no significant effect on subcutaneous fat or BMI. Reported adverse events were arthralgia, myalgia, paresthesia and injection-site reactions, with no serious complications.^[10]

What's being studied next

One new trial is worth knowing about, precisely because it has not produced anything yet. TRIUMPH (NCT06554717) is a Phase 2, randomized, placebo-controlled trial at Massachusetts General Hospital enrolling 100 sedentary adults aged 50-80 with HIV who are frail or at risk, with excess abdominal adiposity. Tesamorelin or placebo is layered on top of a 24-week supervised home exercise program, with muscle fat and mitochondrial function measured at week 24 and physical function at weeks 24 and 48.^[12]

The protocol paper was published in July 2026. The trial is recruiting. Primary completion is not until June 2028.

We are flagging it for one reason: a published protocol is not a result. TRIUMPH tells you what a serious research group thinks is worth asking — whether tesamorelin improves physical function and muscle quality, not just fat distribution — and nothing at all about the answer. If you encounter TRIUMPH cited as evidence that tesamorelin builds muscle or reverses frailty, that citation is being misused.

The NAFLD data

The Stanley 2019 trial deserves special attention because NAFLD (non-alcoholic fatty liver disease) is one of the most common liver conditions globally, and pharmacological treatments are limited.^[4]

In 61 HIV-infected adults with NAFLD (liver fat >= 5%), tesamorelin 2 mg daily for 12 months produced:

• 37% relative reduction in hepatic fat fraction vs placebo (P=0.02)
• 35% of tesamorelin patients resolved NAFLD entirely (liver fat below 5%) vs only 4% on placebo
• Fibrosis protection: only 2 tesamorelin patients experienced fibrosis onset or worsening, compared to 9 in the placebo group

A Phase 2 trial (NCT03375788) exploring tesamorelin for NASH (non-alcoholic steatohepatitis) more broadly was registered; we have not confirmed its current status or seen published results. If the liver findings replicate and extend to non-HIV populations, it would represent a significant expansion of tesamorelin's clinical utility — but as of August 2026 there has been no FDA action, no new indication, and no NASH or MASH label expansion.

The cognition data

The cognition story has moved, and not in tesamorelin's favor. It now reads as one positive trial followed by two that missed.

The Baker 2012 trial (n=152) in healthy older adults and those with MCI showed statistically significant improvement in executive function, with tesamorelin increasing IGF-1 by 117% — and IGF-1 is known to promote brain angiogenesis, neurite outgrowth, and synaptogenesis. That result is what opened this research avenue.^[3]

The Ellis 2025 trial, which examined cognition in HIV patients with abdominal obesity, found only a non-significant trend toward improvement. The between-group difference was not statistically significant (P=0.673), though the tesamorelin group did show a greater reduction in waist circumference.^[7]

Then in 2026, a double-blind, placebo-controlled pilot in 22 adults spanning cognitively normal to mild cognitive impairment tested a low dose (1 mg) of a GHRH analog for 10 weeks. Direct treatment effects on the primary cognitive measures were not significant. The only positive signal came from an exploratory machine-learning analysis suggesting treatment-related differences in right anterior cingulate and left superior frontal-occipital fasciculus connectivity — a hypothesis-generating result in a very small sample, not a finding.^[11]

---

What the evidence shows

People encounter tesamorelin through different lenses — HIV treatment, off-label fat loss, cognitive enhancement, or liver health. Here's what the published research actually supports:

---

Safety & side effects

What the Phase 3 data shows

Tesamorelin has the most comprehensive safety dataset of any GHRH analog, documented in its FDA-approved prescribing information from Phase 3 trials (n=806) with 52-week follow-up:^[14]

Common adverse events (from prescribing information):

• Injection-site reactions: erythema, pruritus, pain, irritation (~24.5% in first 26 weeks, declining to ~6.1% in second 26 weeks)
• Arthralgia (joint pain)
• Peripheral edema (fluid retention)
• Myalgia (muscle pain)
• Paresthesia (tingling or numbness)
• Carpal tunnel syndrome (related to GH effects on tissue turgor)

The current EGRIFTA WR label (revised 3/2025, unchanged since) carries no boxed warning.

The neoplasm and IGF-1 warnings

These get less attention than the diabetes signal, and for an off-label user they are arguably the more important pair.

The label's warnings and precautions include an increased risk of neoplasms, with the instruction to consider carefully whether to initiate treatment in patients with a history of malignancy. It also requires periodic monitoring of IGF-1 levels, because tesamorelin works by raising GH and therefore IGF-1 — in the 2012 cognition trial, IGF-1 rose 117% in the MCI group.

The logic is straightforward and applies to every GH-elevating compound: IGF-1 is a growth factor. Sustained elevation is the mechanism by which tesamorelin does what it does, and it is also the mechanism behind the theoretical cancer concern. In the approved indication, that trade-off is made deliberately by a clinician monitoring a patient with a documented medical need. In off-label wellness use, IGF-1 is often not monitored at all.

The label also warns about fluid retention (edema, carpal tunnel) and notes increased mortality in patients with acute critical illness. Long-term cardiovascular safety has not been established.

The glucose and diabetes concern

This is the most clinically significant safety issue. From the Phase 3 data:^[2]

• Patients receiving tesamorelin had an increased risk of developing diabetes (HbA1c >= 6.5%) compared with placebo: 5% vs 1%, hazard ratio of 3.3
• Fasting glucose increases were observed, though mean changes were modest
• The prescribing information recommends evaluating HbA1c before and during treatment

Reconciling two findings that look contradictory. The 2026 meta-analysis reported no glucose disturbances across its five pooled RCTs, which sits awkwardly next to the HR of 3.3 above. Both are correct, and the difference is duration. The HR comes from the long-term Phase 3 extension data captured in the FDA label, where patients were followed to 52 weeks; the meta-analysis pools trials that were mostly shorter. The practical reading is that glucose effects emerge with sustained exposure rather than appearing early — which is an argument for monitoring HbA1c over time, not for relaxing about it.^[10]

Antibody formation

Anti-tesamorelin IgG antibodies were detected in approximately 49.5% of patients treated for 26 weeks and 47.4% at 52 weeks. In most cases, these antibodies are non-neutralizing and do not affect efficacy. However, in the Phase 3 trials, some patients with anti-tesamorelin antibodies did show reduced treatment response. This is similar to the antibody formation seen with sermorelin.^[14]

Treatment discontinuation

The safety profile supports long-term use for most patients: discontinuation due to adverse events was 9.6% for tesamorelin vs 6.8% for placebo in the first 26 weeks — a modest difference indicating that most adverse events are manageable.

Contraindications and interactions

Contraindications (from prescribing information):

• Active malignancy (GH can stimulate tumor growth). Tesamorelin should be discontinued if a malignancy is diagnosed.
• Disruption of the hypothalamic-pituitary axis due to conditions including hypophysectomy, pituitary tumor/surgery, head irradiation, or trauma
• Pregnancy (Category X — potential fetal harm)
• Known hypersensitivity to tesamorelin or mannitol

Key precautions:

• Monitor glucose and HbA1c before and during treatment
• Fluid retention (edema, carpal tunnel) — typically resolves with dose adjustment or discontinuation
• GH may alter thyroid hormone metabolism — monitor thyroid function
• Potential interaction with glucocorticoids (may blunt GH response)

---

How people use it

Tesamorelin exists in two distinct usage contexts: its FDA-approved indication and off-label use.

FDA-approved use

For HIV-associated lipodystrophy, tesamorelin (Egrifta / Egrifta WR) is prescribed at 2 mg subcutaneously once daily, injected into the abdomen. The newest formulation (Egrifta WR, approved March 2025) allows weekly reconstitution of a multi-dose vial, reducing the preparation burden from daily to weekly.

Treatment is ongoing — the prescribing label notes that fat accumulation returns when treatment is discontinued, so this is a maintenance therapy, not a cure.

Off-label context

Tesamorelin is increasingly prescribed off-label through anti-aging clinics and telehealth providers for:

• General visceral fat reduction (non-HIV)
• Body composition optimization
• NAFLD/fatty liver (emerging indication)
• Cognitive support (limited evidence)

Common stacking context

In clinical practice, tesamorelin is sometimes discussed alongside other GH-related compounds:

• Tesamorelin alone — most common for the approved indication. The Phase 3 data is for tesamorelin monotherapy.
• Tesamorelin + Ipamorelin — complementary GHRH + ghrelin receptor pathways. No controlled trials of this combination exist.
• Tesamorelin vs. Sermorelin — same GHRH pathway, but tesamorelin has an active FDA approval, a longer half-life, and a much larger evidence base. Higher cost.

All combination protocols are based on clinical practice and mechanistic reasoning, not controlled studies.

If you plan to reconstitute peptides, see our reconstitution guide for safety-first preparation instructions.

---

Legal & regulatory status

As of August 2026:

FDA status

Tesamorelin is currently FDA-approved as Egrifta / Egrifta WR for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is the only GHRH analog with an active FDA approval — a critical distinction from sermorelin (withdrawn 2008) and CJC-1295 (never approved).^[14]

The approval history:

1. November 2010: Original Egrifta approval (NDA 022505)
2. 2019: Egrifta SV (single-vial reformulation)
3. March 2025: Egrifta WR (tesamorelin F8, weekly reconstitution formulation)

The label has not changed since that March 2025 revision. Checking again in August 2026: no FDA action of any kind, no new indication, no label expansion, and no boxed warning.

Tesamorelin is available both as the branded product (Egrifta WR) through specialty pharmacies and through compounding pharmacies with a valid prescription. Off-label use for non-HIV indications is at physician discretion.

A note on the manufacturer. Theratechnologies Inc. (Montréal) remains the labeler of record on the current FDA label, so that name on your prescription is correct. It is reported to have been acquired in September 2025 and to have ceased trading publicly; we have not verified this against a primary filing, so treat it as reported rather than confirmed. The practical consequence, if accurate, is that the public quarterly disclosures that previously made it easy to track Egrifta's commercial status no longer exist. We flag this because the absence of corporate news about tesamorelin from here on should not be read as a signal about the drug.

WADA / USADA status

Tesamorelin is prohibited at all times under WADA Section S2.2.4 (growth hormone releasing factors), where the 2026 Prohibited List names it explicitly alongside CJC-1293, CJC-1295 and sermorelin. All S2 substances are non-Specified. This applies to all athletes subject to anti-doping testing. A Therapeutic Use Exemption is technically possible but unlikely, as alternative treatments for GH-related conditions exist.^[15]

International status

Tesamorelin is FDA-approved in the United States. It is available through some international clinics and compounding pharmacies. It is not approved for non-HIV indications in any country.

---

How tesamorelin compares

Tesamorelin exists in a landscape of GHRH-pathway peptides. Here's how it compares to the most relevant alternatives:

The comparison illustrates why tesamorelin's evidence base matters. Both are GHRH analogs working through the same receptor, but tesamorelin has an active FDA approval, Phase 3 trials with 806 patients, a maintained prescribing label, and ongoing post-market safety surveillance. Sermorelin's adult evidence rests on trials with 11-19 participants and a pediatric approval that was withdrawn for commercial reasons.

For someone choosing between GHRH-pathway peptides, tesamorelin has the stronger evidence — but it is also significantly more expensive and its off-label access may be more limited. Sermorelin is more widely available through compounding pharmacies at lower cost, with a longer track record in the anti-aging clinic space.

---

Common exaggerations to watch for

Tesamorelin is sometimes marketed with claims that go beyond the evidence. Here are the most common ones:

• "FDA-approved for weight loss / anti-aging" — False. The FDA approval is specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is not approved for general weight loss, anti-aging, or body composition in non-HIV adults.
• "Proven to reverse fatty liver disease" — Overstated. One RCT (n=61) showed significant liver fat reduction in HIV patients with NAFLD. Promising, but not yet proven in the broader NAFLD population and not an approved indication.
• "Boosts brain function and prevents cognitive decline" — Not supported by the current record. One 2012 trial showed modest executive function improvement. Two later trials — a 2025 Phase 2 and a 2026 placebo-controlled pilot — both failed to show a significant between-group cognitive effect. One positive result followed by two misses is not a foundation for a cognitive claim.
• "No side effects — completely natural" — False. Phase 3 data documents injection-site reactions (~25%), arthralgia, edema, and a 3.3x increased risk of diabetes. These are manageable for most patients but real.
• "Works for everyone who wants to lose belly fat" — The evidence is strongest in HIV patients with lipodystrophy and in non-HIV adults with documented reduced GH secretion. Whether tesamorelin meaningfully reduces visceral fat in healthy adults with normal GH levels is not established.

---

Related content

Peptide

Sermorelin Profile

The other GHRH analog — previously FDA-approved (now withdrawn), 29 amino acids vs tesamorelin's 44. Compare their regulatory histories and evidence bases.

Guide

How to Reconstitute Peptides

A clear, safety-first guide to preparing lyophilized peptides. Essential reading if you're working with injectable peptides.

News

FDA Peptide Categories Explained

Tesamorelin's unique position as an FDA-approved growth hormone secretagogue.

Tool

Reconstitution Calculator

Calculate exact syringe units for tesamorelin reconstitution.

---

References

1. [1]

   Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al.. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” N Engl J Med. 2007. 357(23):2359-2370 DOI PubMedRCT

   First pivotal Phase 3 RCT. n=412, 26-week placebo-controlled. Published in NEJM. High-quality evidence for HIV lipodystrophy indication.

2. [2]

   Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, et al.. “Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials with safety extension data.” J Clin Endocrinol Metab. 2010. 95(9):4291-4304 DOI PubMedRCT

   Pooled analysis of both pivotal trials. n=806 total, 52-week extension. Definitive efficacy and safety dataset for FDA approval.

3. [3]

   Baker LD, Barsness SM, Borber S, Trittschuh EH, Espeland MA, Claxton A, et al.. “Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.” Arch Neurol. 2012. 69(11):1420-1429 DOI PubMedRCT

   Well-designed RCT, n=152, 20 weeks. Positive results for executive function. Largest cognitive trial with a GHRH analog.

4. [4]

   Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al.. “Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.” Lancet HIV. 2019. 6(12):e821-e830 DOI PubMedRCT

   RCT, n=61, 12 months. Well-designed but moderate sample size. Published in Lancet HIV. Clinically significant endpoints (NAFLD resolution, fibrosis prevention).

5. [5]

   Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, et al.. “The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV.” J Frailty Aging. 2019. 8(3):154-159 DOI PubMedRCT

   Secondary analysis from Phase 3 trials. Demonstrates muscle composition improvements beyond visceral fat reduction.

6. [6]

   Makimura H, Stanley TL, Sun N, Feldpausch MN, Grinspoon SK. “Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.” J Clin Endocrinol Metab. 2012. 97(12):4769-4779 DOI PubMedRCT

   RCT, n=60, 12 months. Only published RCT in non-HIV obese adults. Important for extrapolating beyond HIV indication.

7. [7]

   Ellis RJ, Marquine MJ, Engstrom A, et al.. “Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity.” J Infect Dis. 2025. 231(5):1230-1240 DOI PubMedRCT

   Phase 2, open-label. Trend toward cognitive improvement but between-group difference not significant. Open-label design limits interpretation.

8. [8]

   Spooner LM, Olin JL. “Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.” Ann Pharmacother. 2012. 46(2):240-247 DOI PubMedReview

   Comprehensive clinical review covering mechanism, pharmacokinetics, efficacy, and safety. Good overview reference.

9. [9]

   Bedimo R. “Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.” HIV AIDS (Auckl). 2011. 3:69-79 DOI PubMedReview

   Review covering GH and tesamorelin in the context of HIV lipodystrophy management.

10. [10]

    Badran AS, Helal A, Shata KS, Ayesh H. “Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.” Obes Res Clin Pract. 2026. 20(1):2-12 DOI PubMedSystematic review

    Most recent meta-analysis (5 RCTs). Confirms VAT reduction -27.71 cm2 (95% CI -38.37, -17.06), lower trunk fat, higher lean body mass and reduced hepatic fat percentage, with no significant effect on subcutaneous fat or BMI. Reported adverse events were arthralgia, myalgia, paresthesia and injection-site reactions, with no serious complications and no glucose disturbances across the pooled trials.

11. [11]

    Stewart CE, French KP, Wright TJ, Wilhoit K, Randolph KM, Danesi CP, et al.. “The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults across the cognitive spectrum.” eNeurologicalSci. 2026. 44:100616 DOI PubMedPilot study

    Double-blind, placebo-controlled pilot, n=22, 10 weeks, 1 mg GHRH analog. Primary cognitive outcomes were not significant; only an exploratory machine-learning connectivity analysis suggested treatment-related differences. Small sample; no NCT number was reported in the abstract.

12. [12]

    Erlandson KM, Gustafson L, Johnson JE, Kulik GL, Khuu V, et al.. “Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a randomised placebo-controlled trial protocol.” BMJ Open. 2026. 16(7):e120740 DOI PubMedRegistered trial (no results)

    Protocol paper only — no results. NCT06554717, Phase 2, N=100, Massachusetts General Hospital. Registry status checked August 15, 2026: recruiting, primary completion June 2028. Nothing here should be read as evidence of effect.

13. [13]

    Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. “Growth hormone secretagogues: history, mechanism of action, and clinical development.” JCSM Rapid Commun. 2020. 3(1):25-37 DOIReview

    Comprehensive review of all GH secretagogues including GHRH analogs. Provides pharmacological context.

14. [14]

    Theratechnologies Inc. (prescribing information). “EGRIFTA WR (tesamorelin for injection) — Full Prescribing Information.” 2025. Link

    Current FDA-approved prescribing label. Definitive source for safety data, dosing, contraindications, and adverse event rates.

15. [15]

    World Anti-Doping Agency. “The 2026 Prohibited List — International Standard (S2.2.4, growth hormone releasing factors).” 2026. Link

    The 2026 List names tesamorelin explicitly in the S2.2.4 bullet for GHRH and its analogues. Prohibited at all times; non-Specified.

---